Integration of Palliative Care into Heart Failure Care: Consensus-Based Recommendations from HFSA Out Now!

Heart Failure Beat: HFpEF: The Future is Now

On the June episode of the Heart Failure Beat, we welcome guests Stuart Prenner, MD and Kavita Sharma, MD to discuss what is quickly becoming the predominant form of heart failure in the United States: Heart Failure with Preserved Ejection Fraction (HFpEF).

HFpEF: The Future is Now

In this month's episode, we welcome guests Stuart Prenner, MD and Kavita Sharma, MD to discuss what is quickly becoming the predominant form of heart failure in the United States: Heart Failure with Preserved Ejection Fraction (HFpEF). As leaders of two of the few HFpEF specialty clinics in the country, Drs. Prenner and Sharma provide a number of insights involving the evaluation and management of HFpEF patients. On Heart Failure Rounds, Michael explores the use of ARNI and MRA drugs in patients with chronic kidney disease and Craig Beavers, PharmD breaks down Troponin and Treatment Effects of Omecamtiv Mecarbil: GALACTIC-HF on the JCF Spotlight.

Listen below and subscribe: Apple PodcastsAmazon Music, SpotifyPodcast Home

Hosts: 

  • Michael Beasley, MD, Assistant Professor of Medicine at the Yale School of Medicine @MHBeasleyMD

  • Priya Umapathi, MD, Assistant Professor in the Division of Cardiology & Advanced Heart Failure and Heart Transplant Cardiologist at Johns Hopkins Hospital @priyaumapathi

Chapters and Guests: 

  • 1:46-7:45 Heart Failure Rounds

    • Michael Beasley, MD, Assistant Professor of Medicine at the Yale School of Medicine
       
  • 7:45-30:10 Featured Interview HFpEF: The Future is Now

    • Stuart B. Prenner, MD, Assistant Professor of Clinical Medicine at the University of Pennsylvania

    • Kavita Sharma, MD, Associate Professor of Medicine Director at Johns Hopkins Hospital @KSharmaMD
       

  • 30:10-36:56 JCF Spotlight Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study

    • Craig J. Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, Adjunct Assistant Professor at University of Kentucky College of Pharmacy @beaverspharmd


References

  • Felker, G. M., Solomon, S. D., Metra, M., Mcmurray, J. J. V., Diaz, R., Claggett, B., Lanfear, D. E., Vandekerckhove, H., Biering-Sørensen, T., Lopes, R. D., Arias-Mendoza, A., Momomura, S.-I., Corbalan, R., Ramires, F. J. A., Zannad, F., Heitner, S. B., Divanji, P. H., Kupfer, S., Malik, F. I., & Teerlink, J. R. (2024). Cardiac troponin and treatment effects of Omecamtiv Mecarbil: Results from the Galactic-HF Study. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2023.11.021 
  • Matsumoto S, Henderson AD, Shen L, Yang M, Swedberg K, Vaduganathan M, van Veldhuisen DJ, Solomon SD, Pitt B, Zannad F, Jhund PS, McMurray JJV. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function. J Am Coll Cardiol. 2024 Jun 18;83(24):2426-2436. doi: 10.1016/j.jacc.2024.03.426. Epub 2024 May 12. PMID: 38739064
     
  • Chatur S, Neuen BL, Claggett BL, Beldhuis IE, Mc Causland FR, Desai AS, Rouleau JL, Zile MR, Lefkowitz MP, Packer M, McMurray JJV, Solomon SD, Vaduganathan M. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure. J Am Coll Cardiol. 2024 Jun 4;83(22):2148-2159. doi: 10.1016/j.jacc.2024.03.392. Epub 2024 Apr 6. PMID: 38588927.

Guest Disclosures

Alleviant, Bayer, Boehringer-Ingelheim, Cytokinetics, Edward LifeSciences, Eli Lily, Novartis, NovoNordisk, Rivus.

Advisory Board for Astra Zeneca